Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 230

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 230
---
 under any Transaction Document.

3. . Oramed hereby represents and warrants to Purchaser, as of the date
hereof and as of each Closing as follows ( , the representations made as of any Warrant Closing shall be solely as to the Subject Warrants to be assigned in such Warrant Closing):

(a) . Oramed has all necessary corporate power and authority required for Oramed’s due
authorization, execution, delivery and performance of this Agreement and consummation of the Transactions. This Agreement is, and each Assignment Form when executed and delivered by Oramed in connection with the applicable Warrant Closing will be,
duly and validly executed and constitute and he valid and legally binding obligation of Oramed, enforceable in accordance with its terms.

(b) . The Subject Warrants are owned of record and beneficially by Oramed, and Oramed has good and marketable
title to the Subject Warrants, free and clear of any security interest, claims, liens, pledges, options, encumbrances, mortgages, deeds of trust, purchase rights, charges, agreements, voting trusts, proxies or other arrangements or restrictions
whatsoever, other than in favor of Purchaser (collectively, the “”), other than securities law restrictions of general applicability.

(c) . Oramed has not (i) exercised the Subject Warrants, in whole or in part, except with
respect to the partial exercise of the CS-2 Warrant and the CS-5 Warrant on October 30, 2024 for 937,500 shares and 1,062,500 shares, respectively, or
(ii) assigned all or any part of the Subject Warrants or the right to any Common Stock issuable upon exercise of such warrants to any other party.

(d) . The registration statement (the “”) filed by Purchaser covering
the resale of the Warrant Shares by Oramed remains effective and is not subject to any stop order.

(e) .
Oramed has not entered into any agreement, arrangement or understanding with any person or entity which will result in the obligation of Oramed or any Purchaser to pay any finder’s fee, brokerage commission, or fee or expense of any kind in
connection with the Transactions.

5

(f) . The execution, delivery, and performance of this
Agreement by Oramed does not and will not (i) violate applicable law or rule, regulation, order, judgment, injunction, decree or other restriction of any